KALA vs. FDMT, DSGN, CCCC, CRDF, ALMS, OGI, LFCR, CGEN, LRMR, and AMRN
Should you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include 4D Molecular Therapeutics (FDMT), Design Therapeutics (DSGN), C4 Therapeutics (CCCC), Cardiff Oncology (CRDF), Alumis (ALMS), Organigram (OGI), Lifecore Biomedical (LFCR), Compugen (CGEN), Larimar Therapeutics (LRMR), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.
KALA BIO vs.
KALA BIO (NASDAQ:KALA) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations.
24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 8.3% of KALA BIO shares are owned by insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, 4D Molecular Therapeutics had 5 more articles in the media than KALA BIO. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 1 mentions for KALA BIO. 4D Molecular Therapeutics' average media sentiment score of 0.52 beat KALA BIO's score of 0.15 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.
4D Molecular Therapeutics' return on equity of -28.00% beat KALA BIO's return on equity.
KALA BIO has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.
KALA BIO received 249 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 66.89% of users gave KALA BIO an outperform vote while only 66.67% of users gave 4D Molecular Therapeutics an outperform vote.
KALA BIO has a beta of -2.03, meaning that its share price is 303% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.81, meaning that its share price is 181% more volatile than the S&P 500.
KALA BIO presently has a consensus price target of $15.00, indicating a potential upside of 125.90%. 4D Molecular Therapeutics has a consensus price target of $32.13, indicating a potential upside of 592.35%. Given 4D Molecular Therapeutics' higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than KALA BIO.
Summary
4D Molecular Therapeutics beats KALA BIO on 10 of the 17 factors compared between the two stocks.
Get KALA BIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KALA BIO Competitors List
Related Companies and Tools
This page (NASDAQ:KALA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free KALA Stock Alerts